Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Lexicon Pharmaceuticals Q3 EPS $(0.04) Beats $(0.07) Estimate, Sales $14.182M Beat $4.649M Estimate

Author: Benzinga Newsdesk | November 06, 2025 07:31am
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.07) by 42.86 percent. This is a 77.78 percent increase over losses of $(0.18) per share from the same period last year. The company reported quarterly sales of $14.182 million which beat the analyst consensus estimate of $4.649 million by 205.04 percent. This is a 710.40 percent increase over sales of $1.750 million the same period last year.

Posted In: LXRX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist